Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Brain Neoplasms × Immunotherapy × Clear all

Phase

Status

Withdrawn 1 Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3 Triple Negative Breast Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Melanoma 1 Lung Neoplasms 1 Lung Diseases 1 Locally Advanced Non-small Cell Lung Cancer 1 Liver Neoplasms 1 Liver Diseases 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Carcinoma, Hepatocellular 1 Brain Neoplasms 1 Adenocarcinoma of Lung 1 Adenocarcinoma 1

Interventions

Radiosurgery 7 Magnetic Resonance Spectroscopy 5 Temozolomide 4 Trastuzumab 3 pembrolizumab 2 fluciclovine F-18 2 Specimen Handling 2 Magnetic Resonance Imaging 2 Carboplatin 2 Aminolevulinic Acid 2 tucatinib 1 thymoglobulin 1 tepotinib 1 temsirolimus 1 sodium thiosulfate 1 ribociclib 1 pazopanib 1 patritumab deruxtecan 1 palbociclib 1 osimertinib 1 neratinib 1 irinotecan sucrosofate 1 gancotamab 1 gallium Ga 68 dotatate 1 gadoterate meglumine 1 gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate 1 gadobenic acid 1 fluoroacetic acid 1 fludarabine phosphate 1 eribulin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04650490 2023-03-02

STICk-IM-NSCLC

Duke University

Phase 2 Withdrawn

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡